- Anxiety
- Stress
- Eating disorders
- Substance use disorder
- Addiction
MedicalResearch.com Interview with:
Lotfi Khemiri
Centre for Psychiatry Research
Stockholm, Sweden
MedicalResearch.com: What is the background for this study?
Response: Our study used large-scale national register data in close to 2 million children, and found that parental abuse of both alcohol and drugs are associated with increased risk of intellectual disability in the offspring. Importantly, the risk increase was observed in both mothers and fathers which to the best of our knowledge is a novel finding, and may be explained by both genetic and environmental factors including toxic effects of substance intake on fetal development.
Here are two fun facts about the brain--No.1--60%of the human brain is made of fat--and--No.2--brain information travels up to an impressive...
Dr. Huizhong Tao[/caption]
Huizhong Whit Tao, PhD
Professor of Physiology & Neuroscience
Zilkha Neurogenetic Institute
Department of Physiology & Neurosience
Keck School of Medicine
University of Southern California
MedicalResearch.com: What is the background for this study?
Response: Previously, we published a study in which we found that a group of neurons, namely glutamatergic neurons, in the medial preoptic area (MPOA) of the hypothalamus mediate stress-induced anxiety states. This result inspired us to explore whether the MPOA can play a more general role in mood regulation. Fluctuations in the productive hormones secreted by women’s ovaries are known to cause mood swings.
In some cases, rapid changes in the secretion of ovarian hormones can cause depressive-like symptoms. Key examples are postpartum and peri-menopausal depression. In this study, we intended to test whether the MPOA can also play a part in depressive states that are linked to fluctuations in ovarian hormones.
It is estimated that phobias affect 7.8 American adults per year making it an extremely common cause of mental illness among the...
Prof. Leon[/caption]
Michael Leon, Professor emeritus
Dr. Callaghan[/caption]
Bridget Callaghan Ph.D.
Assistant Professor of Psychology
UCLA
Dr. Callahan studies interactions between mental and physical health across development.
MedicalResearch.com: What is the background for this study?
Response: A growing body of evidence links the gut microbiome to brain and immune functioning, and changes to that community of microorganisms is likely among the ways that hardship affects children’s socioemotional development.
Limited evidence in humans has demonstrated the adversities experienced prenatally and during early life influence the composition of the gut microbiome, but no studies had examined whether stress experienced in a mother's own childhood could influence the microbiome of the next generation of children.
Dr. Kruger[/caption]
Jessica Kruger PhD
Clinical Associate Professor of Community Health and Health Behavior
University at Buffalo School of Public Health and Health Professions
MedicalResearch.com: What is the background for this study?
Response: The 2018 Farm Bill authorizing hemp production led to new cannabinoids in the consumer marketplace. As the market becomes increasingly saturated with suppliers, companies continually diversify available products.
The rapid emergence of novel cannabinoids outpaces systematic research necessary to inform regulations and harm reduction. Empirical evidence is needed to guide policies, practices, and education of consumers. Product manufacturers, social media participants, and cannabis oriented on-line news sources have claimed that THC-O-acetate is a "psychedelic" cannabinoid, producing experiences similar to those associated with LSD, psilocybin, mescaline, and DMT.
Valentina Paz[/caption]
Valentina Paz, M.Sc Ph.D. Student
Research and teaching assistant
Universidad de la República, UruguayHon. Research Assistant
Dr. Ogedegbe[/caption]
Gbenga Ogedegbe, MD, MPH
Dr. Adolph & Margaret Berger Professor of Population Health
Director, Division of Health & Behavior
Director Center for Healthful Behavior Change
Department of Population Health
NYU Langone Health
NYU School of Medicine
Member of the U.S. Preventive Services Task Force
MedicalResearch.com: What is the background for this study?
Response: Depression and anxiety disorders are common mental health conditions affecting the lives of many adults in the U.S. The Task Force cares deeply about the health of people nationwide, so we reviewed the latest evidence on how best to support the mental health of adults in primary care.
MedicalResearch.com: What are the main findings?
Response: The evidence shows us that all adults should be screened for depression and those under 65 should also be screened for anxiety. These recommendations apply to everyone without signs or symptoms of depression or anxiety. We also strongly encourage anyone who has signs of depression or anxiety to talk with their clinician so that they can get the care they need.
Dr. Whiteley[/caption]
Alexandra M Whiteley PhD
Department of Biochemistry
University of Colorado Boulder
Boulder, Colorado
MedicalResearch.com: What is the background for this study?
Response: My laboratory was interested in understanding how UBQLN2 maintains cellular health. Ubiquilins facilitate protein degradation, but the precise proteins that they help to break down were not well understood. UBQLN2 is of particular interest because mutations in the UBQLN2 gene lead to a familial form of ALS.
This project, which was published in eLife this year, stems from work that was published when I was a postdoctoral researcher at Harvard Medical School, where we found a link between UBQLN2 and the virus-like protein PEG10. Now at the University of Colorado, Boulder, my laboratory has focused on trying to understand this connection between the two proteins, and how PEG10 could contribute to ALS.
Dr. Bellaver[/caption]
Bruna Bellaver PhD
Postdoctoral associate Department of Psychiatry
University of Pittsburgh
Tharick Pascoal, MD, Ph.D.
Neurologist and assistant professor of Neurology and Psychiatry
University of Pittsburgh School of Medicine.
MedicalResearch.com: What is the background for this study?
Response: Amyloid-β (Aβ) deposition is considered one of the markers of Alzheimer’s disease pathology in the brain. The sequential order of this cascade includes the development of tau pathology and consequent cognitive decline.
However, many people with Aβ deposition in the brain do not progress in the disease, suggesting that other biological processes are playing a role in these pathological events. In vitro evidence suggests that reactive astrocytes unleash Aβ effects in pathological tau phosphorylation.
We found that, in cognitively healthy individuals, Aβ is associated with tau pathology only in individuals with increased astrocyte reactivity.
Joanna Gorgol[/caption]
Joanna Gorgol
PhD Student
University of Warsaw
MedicalResearch.com: What is the background for this study?
Response: People differ in the time when they prefer to wake up and fall asleep: some people prefer going to bed and waking up early, while others prefer later hours. Most of the population is somewhere between them. Research indicates that being a morning person is related to reporting higher satisfaction with life and conscientiousness. Studies also show the associations between being religious and having higher life satisfaction and conscientiousness. It seems that religiosity might mediate the relationship between morningness and higher life satisfaction. To better understand these associations we conducted two questionnaire-based studies of Polish adults, one with 500 participants and the other with 728 participants. All participants completed questionnaires measuring their chronotype, satisfaction with life, personality traits, and religiosity
Dr. Manson[/caption]
JoAnn E. Manson, MD, DrPH, MACP
Chief, Division of Preventive Medicine
Brigham and Women's Hospital
Professor of Medicine and the
Michael and Lee Bell Professor of Women's Health
Harvard Medical School
Boston, Massachusetts 02215
MedicalResearch.com: What is the background for this study? Any particular types of vitamins, ie with/without iron etc?
Response: Preserving memory and cognitive health is a high priority for most mid-life and older adults. However, few strategies have been rigorously tested in randomized clinical trials and shown to have cognitive benefits. Nutritional approaches hold promise because the brain requires several nutrients for optimal health, and deficiencies in one or more of these nutrients may lead to accelerated memory loss and cognitive decline. The COcoa Supplement and Multivitamin Outcomes Study (COSMOS), a large-scale nation-wide randomized trial of multivitamins and cocoa flavanols had recently reported that multivitamins slowed global cognitive decline and memory loss (in COSMOS-Mind). The current study was a 2nd parallel trial, a collaboration between Brigham and Women’s Hospital and Columbia University, looking at a web-based assessment of the role of a standard multivitamin and of cocoa flavanols in slowing age-related memory loss. The report in AJCN is on the multivitamin-cognition findings. The multivitamin tested was Centrum silver for adults (without iron).
Dr. Smith[/caption]
Ruben Smith MD, PhD
Associate professor at Clinical Memory Research
Division of Neurology
Lund University
MedicalResearch.com: What is the background for this study?
Response: Since a few years it has become possible to visualize tau pathology in Alzheimer’s Disease (AD) using positron emission tomography (PET). The tau-PET radiotracer Flortaucipir (Tauvid) was recently approved by the US Food and Drug Administration as an AD diagnostic tool. Since PET imaging is costly and exposes the patient to radioactivity we wanted to study the added clinical value of tau-PET in the diagnostic work-up of patients with cognitive symptoms, before widespread implementation in clinical practice.
Julia Cave Arbanas[/caption]
Julia Cave Arbanas
Project Manager and
John N. Mafi, MD, MPH
Associate Professor of Medicine
General Internal Medicine & Health Services Research
David Geffen School of Medicine at UCLA
MedicalResearch.com: What is the background for this study? What is lecanemab used for and how well does it work?
Response: Lecanemab is a treatment for mild cognitive impairment and mild dementia that was approved in January 2023 as part of the Food and Drug Administration’s (FDA) accelerated approval program. The results from a recent phase 3 clinical trial show a modest clinical benefit: the rate of cognitive decline by 27% in an 18-month study involving participants experiencing the early stage of Alzheimer’s, with an 0.45-point absolute difference in cognitive testing scores. However, due to the risk of brain swelling and bleeding (also known as amyloid-related imaging abnormalities), treatment with lecanemab involves frequent MRIs and neurology or geriatrics appointments to monitor for these abnormalities, which can be life threatening. So far, three patient deaths have potentially been tied to lecanemab.
It is likely that the FDA will grant is lecanemab traditional approval later this year, prompting Medicare to reconsider its current coverage restrictions and potentially enabling widespread use.
Dr. Yuan Changzheng[/caption]
Yuan Changzheng ScD, MSc, B.M.
Research Professor
Doctoral supervisor, School of Medicine
Zhejiang University School of Public Health
Adjunct assistant professor
Harvard T.H. Chan School of Public Health
MedicalResearch.com: What is the background for this study?
Response: The prevention of all-cause dementia is important as it poses substantial burdens on healthcare systems and threatens the well-being of older adults, and lack of effective treatments makes its prevention crucial. The Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet is a hybrid of the Mediterranean diet and the DASH diet, and it emphasizes natural plant-based foods, limited intake of certain animal foods and foods high in saturated fat and encourages consumption of berries and green leafy vegetables rich in vitamins and antioxidants. The MIND diet has previously been associated with lower risk of Alzheimer's disease and slower cognitive decline but few studies have examined its association with all-cause dementia or AD with inconclusive results.
Dr. Esteban McCabe[/caption]
Sean Esteban McCabe, PhD
Director, Center for the Study of Drugs, Alcohol, Smoking and Health
Department of Health Behavior and Biological Sciences
University of Michigan School of Nursing
Ann Arbor, MI
MedicalResearch.com: What is the background for this study?
Response: Prescription stimulant therapy for ADHD helps millions of people, including in my own family, and students, friends and colleagues. It's critical to balance the need for access to these medications while reducing the risk for misuse. This is more important than ever now because there have been recent increases in the prescribing of stimulant therapy for ADHD. There is a need to understand the prevalence of stimulant therapy for ADHD and prescription stimulant misuse in U.S. middle and high schools.
Dr. Buckley[/caption]
Rachel Buckley, PhD
Assistant Professor
Department of Neurology
Massachusetts General Hospital/Harvard Medical School
MedicalResearch.com: What is the background for this study?
Response: While a fair amount of studies have focused on the effects of menopause and hormone therapy on risk of dementia, far fewer studies have tested their association with the biology of Alzheimer’s disease, namely amyloid and tau. This is critical to know given that it still remains unclear what might be the driving mechanism of the menopause transition on risk for dementia. This is what our study set out to investigate.
This study is one of the first to report a link between women’s age at menopause and tau in the brain, which we measured with positron emission tomography neuroimaging. We found that in multiple areas of the brain that tend to be most likely to show higher tau in women than men, women with earlier age at menopause and elevated levels of amyloid showed higher levels of tau than those who reported an average age at menopause (~50 years in the United States). Women who reported premature menopause (<40 years at menopause onset) exhibited a much higher risk of tau in the brain. This supports the notion that longer exposure to estrogen throughout life might be protective against Alzheimer’s disease.
Dr. Keyes[/caption]
Dr Helen Keyes PhD, AFBPsS, SFHEA
Head of School Psychology & Sport Science
Anglia Ruskin University
Cambridge
MedicalResearch.com: What is the background for this study? What types of sporting events?
Response: The data were collected as part of a large government study looking at a range of measures on health and activities across the UK population. Our study honed in on aspects of wellbeing – life satisfaction, loneliness, happiness, anxiety, a sense that life is worthwhile – as well as whether participants had attended a live sporting event in the last year. The data collected did not differentiate between different types of sport – the positive effects that we report for wellbeing are population-wide across a whole range of sports, from attending a local football match all the way up to elite sporting events.
Alexia Aguilar[/caption]
Alexia Aguilar
Geisinger Commonwealth School of Medicine
Scranton, PA
MedicalResearch.com: What is the background for this study?
Response: Traditional antidepressants like Zoloft and Lexapro have three major drawbacks.
If you have recently been diagnosed with Alzheimer’s disease, or indeed another memory-based illness, you will understandably be feeling as...
Dr. Martens[/caption]
Christopher R. Martens PhD
Assistant Professor
Director, Delaware Center for Cognitive Aging Research
Department of Kinesiology & Applied Physiology
University of Delaware
Newark, DE
MedicalResearch.com: What is the background for this study?
Response: One of the main issues with Alzheimer's disease is an impaired ability to make energy in the brain. NAD+ is critically involved in the creation of energy within cells and there is strong evidence that nicotinamide riboside (NR), a precursor to NAD+, can restore brain function in mice that exhibit similar characteristics as people with Alzheimer's disease.
We had previously studied the effects of NR in healthy older adults and wanted to see whether it is even capable of getting into brain tissue. We used remaining blood samples from our original study and measured the amount of NAD+ within tiny "vesicles" in the blood that we are quite confident originated from the brain and other neural tissue
Dr. Yann Le Guen[/caption]
Yann Le Guen, Ph.D.
Assistant Director, Computational Biology
Quantitative Sciences Unit
Stanford Medicine
MedicalResearch.com: What is the background for this study?
Response: Apart from aging, the strongest contributing factor for late-onset Alzheimer’s disease is a specific allele of the APOE gene, which has three common alleles E2, E3, and E4. While E3 is the most common and considered as the reference, E2 is associated with decreased Alzheimer’s disease risk and E4 is associated with increased Alzheimer’s disease risk. Notably the prevalence of E4 among Alzheimer’s patient is high with about 60% of these carrying at least one E4 allele, while solely about 30% Americans carry one E4 allele. It’s worth emphasizing that individuals with an E4/E4 genotype have an exponential increased in their risk to develop AD (10 times as likely than the reference E3/E3 genotype), and individuals with an E3/E4 genotype have an intermediate risk.
Though, most studies of Alzheimer’s disease genetic have been focused on European ancestry, this is beginning to change thanks to NIH’s efforts to fund more studies in non-European ancestry individuals. Our study built on these recent efforts to assess the Alzheimer disease risk associated with an APOE variant (R145C) present in about ~4% African Americans, but extremely rare in Europeans.
Dr. Pierce[/caption]
Karen Pierce, Ph.D.
Professor, Department of Neurosciences, UCSD
Co-Director, Autism Center of Excellence, UCSD
MedicalResearch.com: What is the background for this study?
Response: The mean age of ASD diagnosis and eventual treatment remains at ~52 months in the United States1 - years beyond the disorder’s prenatal origins2, and beyond the age when it can be reliably diagnosed in many cases3.
Currently the only way to determine if a child has autism spectrum disorder (ASD) is to receive a developmental evaluation from an experienced clinician (usually a licensed clinical psychologist). There are often long waiting lists, and only a small number of clinicians have the experience required to make early-age (i.e., between 12-36 months) diagnoses of ASD. Thus, there are many places in the country as well as world wide wherein children wait months or years to receive a formal diagnosis due to a lack of available expertise. Moreover, diagnostic evaluations are expensive and usually cost the parent and/or insurance approximately ~$2,000 or more per evaluation. Finally, clinical evaluations usually take between 2-3 hours to complete and result in fatigue for both the parent and toddler.
Eye-tracking, which generates biologically-relevant, objective, and quantifiable metrics of both visual and auditory preference profiles in babies and toddlers in just minutes, is a technology that can dramatically change how ASD is diagnosed.
Dr. Zhongshang Yuan[/caption]
Yuan, Zhongshang PhD
Department of Biostatistics
School of Public Health
Shandong University
Jinan, Shandong, China
What is the background for this study?
Response: Comorbidities and genetic correlations between gastrointestinal tract diseases and psychiatric disorders have been widely reported, with the gut-brain axis (GBA) hypothesized as a potential biological basis. However, it is unclear the degree to which the shared genetic determinants contribute to these associations underlying GBA.
Dr. Huang[/caption]
Alison R. Huang, PhD MPH
Senior Research Associate
Cochlear Center for Hearing & Public Health
Department of Epidemiology
Johns Hopkins Bloomberg School of Public Health
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Hearing loss is a critical public health issue affecting two-thirds of older adults over 70 years old. There is growing understanding of a strong link between hearing loss and dementia, which impacts millions of Americans.
Our main findings are that in a nationally representative sample of older adults in the United States from the National Health and Aging Trends Study, every 10 decibel increase in hearing loss was associated with 16% greater prevalence of dementia, such that prevalence of dementia in older adults with moderate or greater hearing loss was 61% higher than prevalence in those with normal hearing.
We also found that in older adults with moderate or greater hearing loss, hearing aid use was associated with a 32% lower prevalence of dementia.
Dr. Grashow[/caption]
Rachel Grashow PhD
Research Scientist
Department of Environmental Health
Football Players Health Study at Harvard University
Harvard T.H. Chan School of Public Health
MedicalResearch.com: What is the background for this study?
Response: Anecdotally, we heard from former NFL players that they felt older than their chronological age. At the same time, doctors and medical care providers treating former players also observed that players appeared clinically older in some health domains. These observations motivated us to ask: despite superior fitness and success as young men, are football players experiencing early aging and living with illness and disability for more years than their non-football peers?